DE68919358D1 - Zusammensetzung zur behandlung der schizophrenie. - Google Patents

Zusammensetzung zur behandlung der schizophrenie.

Info

Publication number
DE68919358D1
DE68919358D1 DE68919358T DE68919358T DE68919358D1 DE 68919358 D1 DE68919358 D1 DE 68919358D1 DE 68919358 T DE68919358 T DE 68919358T DE 68919358 T DE68919358 T DE 68919358T DE 68919358 D1 DE68919358 D1 DE 68919358D1
Authority
DE
Germany
Prior art keywords
pct
composition
sec
date
treating schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68919358T
Other languages
English (en)
Other versions
DE68919358T2 (de
Inventor
Andras Perenyi
Goswami Utpal
Mihaly Arato
Ede Frecska
Jozsef Knoll
Arpad Bela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt filed Critical Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Publication of DE68919358D1 publication Critical patent/DE68919358D1/de
Application granted granted Critical
Publication of DE68919358T2 publication Critical patent/DE68919358T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68919358T 1988-08-17 1989-08-17 Zusammensetzung zur behandlung der schizophrenie. Expired - Fee Related DE68919358T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU884374A HU208484B (en) 1988-08-17 1988-08-17 Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
PCT/HU1989/000044 WO1990001928A1 (en) 1988-08-17 1989-08-17 Composition for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
DE68919358D1 true DE68919358D1 (de) 1994-12-15
DE68919358T2 DE68919358T2 (de) 1995-03-30

Family

ID=10967788

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68919358T Expired - Fee Related DE68919358T2 (de) 1988-08-17 1989-08-17 Zusammensetzung zur behandlung der schizophrenie.

Country Status (10)

Country Link
US (1) US5151419A (de)
EP (1) EP0413771B1 (de)
JP (1) JPH0818977B2 (de)
AT (1) ATE113834T1 (de)
BG (1) BG60423B2 (de)
CA (1) CA1329129C (de)
DE (1) DE68919358T2 (de)
HK (1) HK1003978A1 (de)
HU (1) HU208484B (de)
WO (1) WO1990001928A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
WO1992017169A1 (en) * 1991-04-04 1992-10-15 The University Of Toronto Innovations Foundation Use of deprenyl to maintain, prevent loss, or recover nerve cell function
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
ATE194911T1 (de) * 1993-05-04 2000-08-15 Ceva Sante Animale Anwendung von selegilin in tiermedizin
FR2704756B1 (fr) * 1993-05-04 1995-07-28 Sanofi Elf Utilisation de la sélégiline en médecine vétérinaire.
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
AU4353996A (en) * 1994-12-14 1996-07-03 Bioglan Ireland (R & D) Limited Pharmaceutical tablet formulations for direct compression
AU723047B2 (en) 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
JP3273141B2 (ja) * 1995-03-02 2002-04-08 アール． ピー． シェーラー リミテッド モノアミンオキシダーゼｂインヒビターからなる医薬組成物
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
WO1996040085A2 (en) 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
WO1997017067A1 (en) * 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
CA2290381A1 (en) 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
CA2547053C (en) * 2003-11-25 2014-05-27 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US20070082953A1 (en) * 2003-12-18 2007-04-12 Rudolf-Giesbert Alken Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
USRE48839E1 (en) 2008-05-27 2021-12-07 Intra-Cellular Therapies, Inc Methods and compositions for sleep disorders and other disorders
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
EP2968320B1 (de) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organische verbindungen
KR102495941B1 (ko) 2013-12-03 2023-02-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
PT3125893T (pt) 2014-04-04 2023-11-21 Intra Cellular Therapies Inc Gama-carbolinas fusionadas com heterociclo deuterado como antagonistas de recetores 5-ht2a
KR20180099905A (ko) 2016-01-26 2018-09-05 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
IL297676B2 (en) 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
EP3525763A4 (de) 2016-10-12 2020-06-17 Intra-Cellular Therapies, Inc. Amorphe feste dispersionen
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2019023063A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc organic compounds
MX2020009668A (es) 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Métodos novedosos.
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
WO2019241278A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
EP3843738A4 (de) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Neuartige verfahren
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CA3141223A1 (en) 2019-07-07 2021-01-14 Sharon Mates Novel methods
US11753419B2 (en) 2019-12-11 2023-09-12 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
DE3764144D1 (de) * 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick

Also Published As

Publication number Publication date
EP0413771B1 (de) 1994-11-09
JPH03500897A (ja) 1991-02-28
ATE113834T1 (de) 1994-11-15
CA1329129C (en) 1994-05-03
US5151419A (en) 1992-09-29
HUT51136A (en) 1990-04-28
WO1990001928A1 (en) 1990-03-08
EP0413771A1 (de) 1991-02-27
JPH0818977B2 (ja) 1996-02-28
HK1003978A1 (en) 1998-11-13
DE68919358T2 (de) 1995-03-30
HU208484B (en) 1993-11-29
BG60423B2 (bg) 1995-03-31

Similar Documents

Publication Publication Date Title
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE69634269D1 (de) Verfahren zum modulieren der mikrozirkulation
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
MC1930A1 (fr) Produit antiviral
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE58903659D1 (de) Pharmazeutische zubereitung zur behandlung entzuendeter nasenschleimhaeute.
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
KR900017599A (ko) 종양 치료용 약학 조성물
MY110416A (en) Composition for the treatment of schizophrenia.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
CO5040221A1 (es) Sal fumarato de (r)-5-(metilaminosulfonilmetil)-3-(n-metil- pilrrolidin-2-ilmetil)-1h-indol, composiciones farmaceuticas que contienen la misma y un procedimiento para preparar di- cha sal

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee